Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 5/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12489380 | 0.80 | MET (0.41) | METKEAP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2197403 | 0.77 | KEAP1 (0.53) | METKEAP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22652316 | 0.76 | MET (0.39) | METKEAP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19184892 | 0.76 | MET (0.41) | METKEAP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20798951 | 0.75 | MET (0.38) | METKEAP1DYRK1AMEN1CYP1A2 | |
| SCHEMBL2629380 | 0.71 | TGFBR1 (0.43) | METKEAP1DYRK1ATGFBR1MEN1 | |
| SCHEMBL2497836 | 0.70 | MET (0.35) | METKEAP1DYRK1A | |
| SCHEMBL5487376 | 0.66 | DYRK1A (0.40) | METKEAP1DYRK1ATGFBR1DAO | |
| SCHEMBL5488750 | 0.66 | DYRK1A (0.47) | METKEAP1DYRK1ATGFBR1MEN1 | |
| SCHEMBL11266549 | 0.66 | DYRK1A (0.40) | METKEAP1DYRK1ATGFBR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382923-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230159557-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159557-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, BRCA1 | MET 139/4885KEAP1 428/4885NPC1 3640/4885 |
| US-20230382923-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, BRCA1 | MET 139/4885KEAP1 428/4885NPC1 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.